Please check detailed patent information at the following link:
TeanNic Compliance - Wholesale Nicotine Solutions That Meet Global Standards (teanhee.com)
MAOMING, China – July 31, 2026 – Maoming Teanhee Biotechnology Co., Ltd., a leading innovator in synthetic nicotine manufacturing, today announced a significant technological breakthrough in the enzymatic synthesis of S-nicotine. The company has successfully developed a novel non-reducing enzymatic catalyst that enables substantially higher S-enantiomer ratios, while simultaneously completing a comprehensive upgrade of its industrial-scale production processes. Patent applications have been filed to secure the proprietary technology, and the company is now extending full intellectual property protection to its partners worldwide.
Unlike conventional reduction-dependent enzymatic routes, Maoming Teanhee’s newly engineered catalyst operates through a non-reducing mechanism, offering distinct advantages in stereoselectivity and reaction stability. Laboratory and pilot-scale validation have consistently demonstrated a significantly elevated S-enantiomer proportion – a critical quality parameter for pharmaceutical-grade and premium nicotine applications. The catalyst’s unique performance profile not only enhances chiral purity but also simplifies downstream purification, reducing overall production complexity.
To bring this innovation from lab to market, the company has upgraded its entire industrial manufacturing platform, including reactor design, enzyme immobilization techniques, and process control systems. These enhancements ensure consistent, reproducible results at metric-ton scale, making the breakthrough immediately relevant for commercial supply.
In parallel with the R&D achievements, Maoming Teanhee has filed patent applications (official numbers to be announced) covering the novel enzyme, its production method, and the associated synthetic pathway. This move forms a cornerstone of the company’s intellectual property strategy, providing comprehensive legal protection for its partners. By securing exclusive rights to the core technology, the company guarantees that customers can source S nicotine with confidence, free from infringement risks and backed by enforceable IP safeguards.
Process optimization has yielded substantial reductions in manufacturing costs across the entire production chain – from raw material utilization to energy consumption and waste management. The combination of higher enantioselectivity, improved yields, and streamlined operations allows Maoming Teanhee to offer superior-quality synthetic nicotine at more competitive prices, without sacrificing purity, consistency, or regulatory compliance. This value proposition is designed to empower partners in the e-liquid, pharmaceutical, and research sectors.
The technological and industrial advancements lay a solid foundation for the international expansion of the TEANNIC brand. Positioned as a premium synthetic nicotine label, TEANNIC will leverage the new enzymatic platform to deliver products that meet the highest global standards. The breakthrough reinforces Maoming Teanhee’s reputation as a reliable, forward-thinking supplier ready to serve customers across North America, Europe, and Asia.
“Our new non-reducing enzymatic catalyst represents a paradigm shift in S-nicotine production,” said ALEX, CTO of Maoming Teanhee Biotechnology. “We have moved beyond traditional enzymatic routes to create a solution that is not only more selective and scalable but also more cost-effective. Combined with our robust IP protection and industrial upgrades, we are excited to offer our partners a truly differentiated product – and to build the TEANNIC brand as a symbol of quality and trust worldwide.”
Maoming Teanhee Biotechnology welcomes inquiries from manufacturers, brand owners, and distributors seeking high-purity, IP-secured synthetic nicotine. The company’s technical and commercial teams are available to discuss custom specifications, supply agreements, and collaborative development opportunities.
About Maoming Teanhee Biotechnology Co., Ltd.
Maoming Teanhee Biotechnology Co., Ltd. is a China-based advanced manufacturer specializing in the research, development, and production of synthetic nicotine and related chiral compounds. Committed to green chemistry and enzymatic innovation, the company serves a global clientele with high purity nicotine products under the TEANNIC brand, and continuously invests in next-generation production technologies to meet evolving market demands.
Media and Partnership Inquiries:
Email: [Insert contact email]
Website: [Insert company website]
Phone: [Insert contact number]
